DOSIsoft Launches DOSIsoft Theranostics for Personalized Nuclear Medicine
DOSIsoft has launched DOSIsoft Theranostics, a dedicated organization focused on advancing software for personalized nuclear medicine and theranostics, announced in a press release. The new entity aims to accelerate innovation and expand clinical adoption of radiopharmaceutical therapy solutions.
DOSIsoft Theranostics will operate independently, developing tools that integrate diagnostics and targeted therapies to support routine clinical workflows. The organization will focus on software for individualized therapy monitoring across different imaging modalities and treatment cycles.
At the center of the new entity’s portfolio is PLANET, DOSIsoft’s FDA cleared and CE marked platform that supports multi radionuclide dosimetry and multimodality DICOM interoperability. PLANET is already used in hospitals and research centers worldwide with a vendor neutral design that accommodates diverse clinical workflows.
DOSIsoft Theranostics will present its solutions at SNMMI 2026 and continue to collaborate with hospitals and research institutions to support quantitative imaging and personalized care in nuclear medicine.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Sales & Marketing AI Weekly or Daily AI Brief.
Also, consider following us on social media:
Sales & Marketing AI Weekly
News about AI tools and innovations for Sales and Marketing professionals.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
XtalPi Launches Kodexia siRNA Discovery Platform
Suvoda Updates Clinical Trial Platform With AI and Unified Access
Suvoda Expands Sofia to All New RTSM and eCOA Trials
MediSights Reports Study Using AI Agents for Myeloma Market Research
Daily AI Brief: the AI news that matters, in your inbox.